MNG177
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.571
- INTERFERON_GAMMA_RESPONSE+0.479
- UV_RESPONSE_DN+0.309
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.293
- IL6_JAK_STAT3_SIGNALING+0.258
- TGF_BETA_SIGNALING+0.211
- ADIPOGENESIS+0.201
- PROTEIN_SECRETION+0.200
- PEROXISOME+0.181
- MYOGENESIS+0.166
Top 10 suppressed
- MYC_TARGETS_V2-0.243
- MYC_TARGETS_V1-0.228
- MTORC1_SIGNALING-0.204
- SPERMATOGENESIS-0.200
- PANCREAS_BETA_CELLS-0.194
- TNFA_SIGNALING_VIA_NFKB-0.144
- G2M_CHECKPOINT-0.121
- ESTROGEN_RESPONSE_LATE-0.099
- APICAL_SURFACE-0.089
- ESTROGEN_RESPONSE_EARLY-0.073
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG385 | — | — | 0.815 |
| 2 | MNG1060 | — | — | 0.766 |
| 3 | MNG827 | — | — | 0.750 |
| 4 | MNG693 | — | — | 0.725 |
| 5 | BS_TYKJ8G2G | Schwannoma | — | 0.720 |
| 6 | 69188 | EPN | Supratentorial EPN | 0.718 |
| 7 | TCGA-50-5941-01A-11R-1755-07 | — | cohortA1 | 0.717 |
| 8 | C3N-01416 | — | cohortA1 | 0.705 |
| 9 | SRR12696729 | — | — | 0.700 |
| 10 | BS_V0Q1G94N | low-grade glioma | — | 0.692 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 31 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.571 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.479 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.309 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.293 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.258 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.211 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.201 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.200 | Remibrutinib | — uncovered |
| PEROXISOME | 0.181 | Idelalisib | — uncovered |
| MYOGENESIS | 0.166 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.160 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.159 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.148 | Idelalisib | — uncovered |
| COMPLEMENT | 0.118 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.104 | Temsirolimus | — uncovered |
| APOPTOSIS | 0.097 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.087 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.087 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_UP | 0.082 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.079 | Inavolisib | — uncovered |